Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplant in Patients With Severe Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient selection~  1. Age \> 18 years~ 2. Patients with Hb SS, Hb SC, Hb Sβ0 genotype~ 3. Presence of at least 1 of the following manifestations:~     1. History of clinically significant neurologic event defined as stroke or any neurological deficit lasting \> 24 hours.~    2. History of two or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures~    3. Three or more pain crises per year in the 2-year period preceding referral (required intravenous pain management in the outpatient or inpatient hospital setting).~        This may include painful episodes related to priapism, osteonecrosis or any sickle-related complication.~    4. An echocardiographic finding of the tricuspid valve regurgitant jet (TRJ) velocity ≥ 2.7 m/sec.~    5. History of osteonecrosis or avascular necrosis of ≥ 2 joints~    6. Administration of regular RBC transfusion therapy, defined as receiving 8 or more transfusions per year for \> 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)~    7. History of RBC allo-immunization but without detectable allo-antibodies.~    8. Evidence of sickle hepatopathy or iron overload in patients who received ≥ 8 packed RBC transfusions for ≥ 1 year or have received ≥ 20 cumulative packed RBC transfusions. These patients will undergo MRI of the liver to estimate liver iron content.~    9. Patients with hepatic iron content of ≤ 7 mg Fe/ gm of liver will be included ii. Patients with hepatic iron content of ≥ 7 mg Fe/ gm of liver will undergo biopsy to look for absence of histological findings suggestive of cirrhosis, fibrosis and active hepatitis~     h. Sickle nephropathy defined as Cr ≥ 1.5 times the ULN or biopsy proven i.Reversible SCD complication not ameliorated by hydroxyurea: i.Two or more vaso-occlusive crises requiring hospitalizations ii. Any episode of ACS while on hydroxyurea~ 4. Adequate physical function as measured by all of the following:~     1. Karnofsky performance score \> or equal to 70~    2. Cardiac function: Left ventricular ejection fraction (LVEF) \> 40%; or LV shortening fraction \> 26% by cardiac echocardiogram or by MUGA scan.~    3. Pulmonary function: Pulse oximetry with a baseline O2 saturation of \> 85%, DLCO \> 40% (corrected for hemoglobin).~    4. Renal function: Serum creatinine ≤ 1.5 x the upper limit of normal for age as per local laboratory and 24 hour urine creatinine clearance \>70 mL/min/1.73 m2; or GFR \> 70 mL/min/1.73 m2 by radionuclide GFR unless reason for transplant is sickle nephropathy~    5. Hepatic function:~     i. Serum conjugated (direct) bilirubin \< 2x upper limit of normal for age as per local laboratory; ii. ALT and AST \< 5 times upper limit of normal. iii. Patients with hyperbilirubinemia because of hyper hemolysis, or who experience a sudden, profound change in the serum hemoglobin after a RBC transfusion are not excluded.~ 5. The HLA matched related donor must be willing to donate and must meet our institutional guidelines to donate peripheral blood stem cells~ 6. Absence of donor specific HLA antibodies.~ 7. Absence of clinical or radiographic evidence of neurologic event within 6 months prior to proceeding with transplantation.~     1. Cerebral MRI/MRA within 6 months prior to initiation of transplant conditioning.~    2. If patient has a neurologic event such as stroke or transient ischemic attack during recruitment process, patient will be deferred for 6 months before reconsideration.~Donor selection~1. Siblings who are ≥18 years and capable and willing to donate PBSC~2. Sibling donors are HLA-matched. HLA-A, B, C, and DRB1 match based on high-resolution typing~3. All sibling donors MUST meet institutional criteria for donation.~4. Donors with sickle cell trait (Hb AS) are permitted.~5. Donors with ABO minor incompatibility are permitted~Exclusion Criteria:~Patient selection~1. Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment.~2. Seropositivity for HIV.~3. Previous stem cell transplantation.~4. Participation in a clinical trial in which the patient received an investigational drug or device~5. A history of substance abuse as defined by version IV of the Diagnostic \& Statistical Manual of Mental Disorders (DSM IV).~6. Demonstrated lack of compliance with prior medical care as determined by referring physician.~7. Pregnant or breast-feeding females.~8. Unwillingness to use approved contraception method from time of conditioning regimen and 4 months after discontinuation of all immunosuppressive medications.~Donor selection A. Inclusion Criteria~1. Siblings who are ≥18 years and capable and willing to donate PBSC~2. Sibling donors are HLA-matched. HLA-A, B, C, and DRB1 match based on high-resolution typing~3. All sibling donors MUST meet institutional criteria for donation.~4. Donors with sickle cell trait (Hb AS) are permitted.~5. Donors with ABO minor incompatibility are permitted~B. Exclusion Criteria~1. Donors with hemoglobinopathies: Hb SS, Hb SC, Hb Sβ0 and all other unstable hemoglobins~2. Presence of anti-donor HLA antibodies in the recipient~3. Donors with major ABO incompatibility are permitted~4. Donors who are HIV-1, HIV-2, HTLV-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non Myeloablative regimen (Alemtuzumab) (Type: EXPERIMENTAL): Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.

Based on this trial design, predict the completion outcome and termination type (if applicable).